Stock Analysis, Dividends, Split History

AMID / American Midstream Partners LP financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)539.16
Enterprise Value ($M)1,588.81
Book Value ($M)112.46
Book Value / Share2.12
Price / Book2.85
NCAV ($M)-1,348.52
NCAV / Share-25.45
Price / NCAV-0.24
Share Statistics
Common Shares Outstanding 52,852,752
Common Shares Outstanding2 9,241,642
Common Shares Outstanding3 11,009,729
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.16
Return on Assets (ROA)-0.14
Return on Equity (ROE)-5.51
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio1.17
Income Statement (mra) ($M)
Revenue From Related Parties2,500,000.00
Revenue Oil And Gas Services154,652,000.00
Sales Revenue Energy Services154,652,000.00
Disposal Group Including Discontinued Operation Revenue0.00
Acquisitionof Assetsand Liabilities Under Common Control Unbilled Revenues0.00
Sales Revenue Net0.00
Disposal Group Including Discontinued Operation Unbilled Revenue Current0.00
Natural Gas Production Revenue496,902,000.00
Operating Income-294.20
Net Income-218.51
Cash Flow Statement (mra) ($M)
Cash From Operations14.99
Cash from Investing252.31
Cash from Financing252.31
Identifiers and Descriptors
Central Index Key (CIK)1513965
Related CUSIPS
02752P950 02752P900

Split History

Stock splits are used by American Midstream Partners LP to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Your 80 Mid-September 10%+ Dividend WallStars By Yield And Target Gains

2018-09-18 seekingalpha
WallStars have positive broker target price upsides. 80 stocks displayed 10%+ forward yield, $2.00+ prices, and $50M+ market caps as of 9/14/18. Yields above 12.2% narrowed the list to 30. (3-0)

10 Energy Sector Top Target Gains Range 24.6%-83.8% From September Dividend WallStars

2018-09-07 seekingalpha
Energy equities with over .72% Broker Target Upsides showed midstream firms tops on the list, Sanchez, for price upside and American Midstream for net gains, and yield as of 9/6/18. (4-1)

10 Oil Stocks That Are Worth a Second Look

2018-09-05 investorplace
The last few weeks have been tricky ones for energy investors. Some oil stocks have struggled, while others have managed to rally. The market has taken each of these names on a case-by-case basis. (8-1)

78 September 10%-Plus Dividend WallStars By Yield And Target Gains

2018-09-04 seekingalpha
WallStars show positive broker target price upsides. 78 stocks displayed 10%+ forward yield, $2.50+ prices, and $50M+ market caps as of 8/31/18. Yields above 12.19% narrowed the list to 30. (4-0)

American Midstream to Acquire Interest in Enterprise's Plant

2018-08-24 zacks
Enterprise Products Partners L.P. (EPD - Free Report) and American Midstream Partners, LP (AMID) have inked an agreement. Per the terms, American Midstream may opt to acquire a 25% interest in Enterprise’s Pascagoula natural gas processing plant. The purchase option may be exercised on fulfillment of certain conditions, which include the completion of alterations to certain facilities on High Point pipeline system by American Midstream.

CUSIP: 02752P100